68Ga-DOTATATE PET Scan for Neuroendocrine Cancer

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Ochsner Health System

No Placebo Group

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

Eligibility Criteria

Adults with neuroendocrine tumors or suspected positive tumors, who can consent and have a moderate level of physical function. Women must not be pregnant. Excluded are those with high creatinine or liver enzyme levels, severe allergies to IV contrast, recent use of investigational products, serious illnesses that could affect participation, active infections, inability to stay still for imaging or fit into the scanner due to size.

Inclusion Criteria

I am able to live at home and care for most of my personal needs.

I am capable of becoming pregnant and have a negative pregnancy test.

I am 18 years old or older.

Exclusion Criteria

I cannot stay still for long periods due to a condition like severe arthritis.

I weigh less than 400 pounds and can fit into a PET/CT scanner.

I currently have an active infection.

Treatment Details

The trial is testing the safety and effectiveness of a new PET scan using 68Ga-DOTATATE compared to standard imaging methods in detecting neuroendocrine tumors. Patients will receive an injection of this tracer dose radiopharmaceutical for tumor imaging.

1Treatment groups

Experimental Treatment

Group I: ScanExperimental Treatment1 Intervention

We will perform 68Ga-DOTATATE PET scans on subjects.